| Title: | Somaxon Pharmaceuticals Inc: Premium Company Profile |
| Price: | $495.00 |
| Publication Date: | Mar 13, 2008 |
| Report Type: | Premium Profile |
| Abstract: | Introduction
Somaxon Pharmaceuticals (Somaxon) is a development stage pharmaceutical company engaged in in-licensing and developing proprietary product candidates for the treatment of psychiatry and neurology disorders. In January 2008, Somaxon submitted NDA with the FDA for Silenor for the treatment of insomnia.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Somaxon Pharmaceuticals enters into licensing agreements with pharmaceutical companies for developing therapeutics. In 2003, the company entered into licensing agreement with ProCom One for the exclusive, worldwide license to certain patents to develop and commercialize low dosages of Silenor for the treatment of insomnia. In the following year, BioTie Therapies granted the license of oral nalmefene hydrochloride to Somaxon. In addition, Somaxon received exclusive worldwide rights from Synchroneuron to certain patents to develop, manufacture and market acamprosate. During the forecast period 2006-2010, Somaxon is expected to derive its entire revenues from the launch of Silenor in 2009. Product sales of Silenor are expected to grow from $71 million in 2009 to $119 million in 2010.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization.
|
| Brief Excerpt: | ...The Feminine Care market consists of Internal Cleansers, Pantiliners and shields, Sanitary Pads and Tampons. ... |
| Word Count: | 25696 |
| Length: | 113 Pages |
| Industry(ies): | Healthcare, Pharmaceutical |
| Format: | 
Adobe Acrobat
|
| Free Sample: |
Click
Here
to Download
|
| Table of Contents: | TABLE OF CONTENTS
Overview 1
Catalyst 1
Summary 1
Company Structure 6
Company Overview and Key Facts 6
Business Description 7
History 8
Company Financials 9
Stock Market Performance 9
P&L 10
Balance Sheet 12
Cash Flow 12
Products & Services 13
Pipeline Products 13
AC Forecast Product Sales 15
Competitors and Strategic Business Relationships 16
Key Competitors 16
Key Suppliers 16
Shareholding Structure 18
Strategy 19
Company View 19
Corporate Strategy 21
SWOT Analysis 22
Overview 22
Strengths 23
Weaknesses 24
Opportunities 25
Threats 26
Value Chain Analysis 27
Overview 27
Product Development 27
Scorecard 28
Overview 28
Scorecard Analysis 28
Key Employees 29
List of Employees 29
Key Employee Biographies 30
Financial and Operational Overview 39
Financial and Operational Overview 39
Appendix 41
Ask the analyst 41
Datamonitor consulting 41
Disclaimer 41
TABLE OF FIGURES
Figure 1: Somaxon Pharmaceuticals - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 11
TABLE OF TABLES
Table 1: Somaxon Pharmaceuticals - Key Facts 6
Table 2: Somaxon Pharmaceuticals - Year-End Share Price and Market Capitalization, 2002-2006 ($) 9
Table 3: Somaxon Pharmaceuticals - Key Events Impacting Share Price Performance 9
Table 4: Somaxon Pharmaceuticals - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 10
Table 5: Somaxon Pharmaceuticals - Balance Sheet 12
Table 6: Somaxon Pharmaceuticals - Cash Flow 12
Table 7: Somaxon Pharmaceuticals - In-house Pipeline Products 13
Table 8: Somaxon Pharmaceuticals - Forecast Sales, 2006-2010 ($ Mn) 15
Table 9: Somaxon Pharmaceuticals - Key Competitors 16
Table 10: Somaxon Pharmaceuticals - Key Suppliers 17
Table 11: Somaxon Pharmaceuticals - Key Shareholders 18
Table 12: Somaxon Pharmaceuticals - SWOT Analysis Summary 22
Table 13: Somaxon Pharmaceuticals - Value Chain Analysis 27
Table 14: Somaxon Pharmaceuticals - Key Employees 29
Table 15: Somaxon Pharmaceuticals- Financial and Operational Overview 39
|
Looking For Something Else?
